Header Logo

Connection

Kathleen Moore to Patient Reported Outcome Measures

Back to Details
This is a "connection" page, showing publications Kathleen Moore has written about Patient Reported Outcome Measures.
Kathleen Moore
Connection Strength
0.200
Patient Reported Outcome Measures
  1. Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer. Gynecol Oncol. 2023 10; 177:20-31.
    View in: PubMed
    Score: 0.200
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.